OncLive SOSS

Genomic Testing for Improved Treatments in Breast Cancer - Episode 5

FLEX Trial: Genomic Testing of HER2 Status in ER+/HER2-Breast Cancer

February 13, 2024

Joyce O’Shaughnessy, MD, Erin Cobain, MD

Expert oncologists discuss genomic testing for patients with HER2-low breast cancer, noting the FLEX trial of MammaPrint and BluePrint.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Evolving Treatment Paradigms for Early-Stage Breast Cancers

EP. 2: Overview of Genomic Assays for Early-Stage Breast Cancer

EP. 3: MammaPrint: A 70-Gene Signature Test for Patient with Breast Cancer

EP. 4: Clinical Considerations of Genomic Testing in Early-Stage Breast Cancer

EP. 5: FLEX Trial: Genomic Testing of HER2 Status in ER+/HER2-Breast Cancer

EP. 6: Exploring Multigene Genomic Assays in High-Risk BC Patients

EP. 7: Real-World Evidence in Genomic Testing from SABCS 2023

EP. 8: Racial Disparities and Genomic Testing for Breast Cancer Patients

EP. 9: Reflecting on Genomic Testing in Practice for Breast Cancer

EP. 10: Ongoing Studies in Genomic Testing for Breast Cancer

x